Interferon alfa receptor expression and growth inhibition by interferon alfa in human liver cancer cell lines

Hepatology

Volumn 29, Issue 6, 1999, Pages 1708-1717

  Yano, H ^a   Iemura, A ^a   Haramaki, M ^a   Ogasawara, S ^a   Takayama, A ^a   Akiba, J ^a   Kojiro, M ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ALPHA INTERFERON RECEPTOR;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL CYCLE; CELL PROLIFERATION; GROWTH INHIBITION; HUMAN; HUMAN CELL; LIVER CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 0032991093     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.510290624     Document Type: Article

References (68)

1. 1 Pestka S, Langer JA, Zoon KC, Samuel CE. Interferons and their actions. Annu Rev Biochem 1987 ; 56: 727–777. MEDLINE
2. 2 Pestka S. The interferon receptors. Semin Oncol 1997 ; 24 (Suppl 9): 18S–40S.
3. 3 Domanski P, Witte M, Kellum M, Rubinstein M, Hackett R, Pitha P, Colamonici OR. Cloning and expression of a long form of the β subunit of the interferon αβ receptor that is required for signaling. J Biol Chem 1995 ; 270: 21606–21611. MEDLINE
4. 4 Lutfalla G, Holland SJ, Cinato E, Monneron D, Reboul J, Rogers NC, Smith JM, et al. Mutant U5A cells are complemented by an interferon‐αβ receptor subunit generated by alternative processing of a new member of a cytokine receptor gene cluster. EMBO J 1995 ; 14: 5100–5108. MEDLINE
5. 5 Novick D, Cohen B, Rubinstein M. The human interferon α/β receptor: characterization and molecular cloning. Cell 1994 ; 77: 391–400. MEDLINE
6. 6 Uzé G, Lutfalla G, Gresser I. Genetic transfer of a functional human interferon α receptor into mouse cells: cloning and expression of its cDNA. Cell 1990 ; 60: 225–234. MEDLINE
7. 7 Schindler C, Darnell JE. Transcriptional responses to polypeptide ligand: the JAK‐STAT pathway. Annu Rev Biochem 1995 ; 64: 621–651. MEDLINE
8. 8 Ihle JN, Kerr IM. Jaks and STATS in signaling by the cytokine receptor superfamily. Trends Genet 1995 ; 11: 69–74. MEDLINE
9. 9 Darnell JE, Kerr IM, Stark GR. Jak‐STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 1994 ; 264: 1415–1421. MEDLINE
10. 10 Harada H, Kitagawa M, Tanaka N, Yamamoto H, Harada K, Ishihara M, Taniguchi T. Anti‐oncogenic and oncogenic potentials of interferon regulatory factors‐1 and ‐2. Science 1993 ; 259: 971–974. MEDLINE
11. 11 Harada H, Fujita T, Miyamoto M, Kimura Y, Maruyama M, Furia A, Miyata T, et al. Structurally similar but functionally distinct factors, IRF‐1 and IRF‐2, bind to the same regulatory elements of IFN and IFN‐inducible genes. Cell 1989 ; 58: 729–739. MEDLINE
12. 12 Miyamoto M, Fujita T, Kimura Y, Maruyama M, Harada H, Sudo Y, Miyata T, et al. Regulated expression of a gene encoding a nuclear factor, IRF‐1, that specifically binds to IFN‐β gene regulatory elements. Cell 1988 ; 54: 903–913. MEDLINE
13. 13 Willman CL, Sever CE, Pallavicini MG, Harada H, Tanaka N, Slovak ML, Yamamoto H, et al. Deletion of IRF‐1, mapping to chromosome 5q31.1, in human leukemia and preleukemic myelodysplasia. Science 1993 ; 259: 968–971. MEDLINE
14. 14 Yamada G, Ogawa M, Akagi K, Miyamoto H, Nakano N, Itoh S, Miyazaki J, et al. Specific deletion of the B‐cell population induced by aberrant expression of human interferon regulatory factor 1 gene in transgenic mice. Proc Natl Acad Sci U S A 1991 ; 88: 532–536. MEDLINE
15. 15 Tanaka N, Ishihara M, Kitagawa M, Harada H, Kimura T, Matsuyama T, Lamphier MS, et al. Cellular commitment to oncogene‐induced transformation or apoptosis is dependent on the transcription factor IRF‐1. Cell 1994 ; 77: 829–839. MEDLINE
16. 16 Tamura T, Ishihara M, Lamphier MS, Tanaka N, Oishi I, Aizawa S, Matsuyama T, et al. An IRF‐1‐dependent pathway of DNA damage‐induced apoptosis in mitogen‐activated T lymphocytes. Nature 1995 ; 376: 596–599. MEDLINE
17. 17 Giandomenico V, Lancillotti F, Fiorucci G, Percario ZA, Rivabene R, Malorni W, Affabris E, et al. Retinoic acid and IFN inhibition of cell proliferation is associated with apoptosis in squamous cell carcinoma cell lines: role of IRF‐1 and TGase II–dependent pathways. Cell Growth Differ 1997 ; 8: 91–100. MEDLINE
18. 18 Gutterman JU. Cytokine therapeutics: lessons from interferon α. Proc Natl Acad Sci U S A 1994 ; 91: 1198–1205. MEDLINE
19. 19 Yatsuhashi H, Yamasaki K, Aritomi T, Carmen PMD, Inoue O, Koga M, Yano M. Quantitative analysis of interferon α/β receptor mRNA in the liver of patients with chronic hepatitis C: correlation with serum hepatitis C virus–RNA levels and response to treatment with interferon. J Gastroenterol Hepatol 1997 ; 12: 460–467. MEDLINE
20. 20 Fukuda R, Ishimura N, Kushiyama Y, Moriyama N, Ishihara S, Nagasawa S, Miyake T, et al. Effectiveness of interferon‐alpha therapy in chronic hepatitis C is associated with the amount of interferon‐alpha receptor mRNA in the liver. J Hepatol 1997 ; 26: 455–461. MEDLINE
21. 21 Shiratori Y, Shiina S, Imamura M, Kato N, Kanai F, Okudaira T, Teratani T, et al. Characteristic difference of hepatocellular carcinoma between hepatitis B‐ and C‐viral infection in Japan. Hepatology 1995 ; 22: 1027–1033. MEDLINE
22. 22 Lai CL, Lau JYN, Wu P, Ngan H, Chung HT, Mitchell SJ, Corbett TJ, et al. Recombinant interferon‐α in inoperable hepatocellular carcinoma: a randomized controlled trial. Hepatology 1993 ; 17: 389–394. MEDLINE
23. 23 Sachs E, Di Bisceglie AM, Dusheiko GM, Song E, Lyons SF, Schoub BD, Kew MC. Treatment of hepatocellular carcinoma with recombinant leucocyte interferon: a pilot study. Br J Cancer 1985 ; 52: 105–109. MEDLINE
24. 24 The Gastrointestinal Tumor Study Group. A prospective trial of recombinant human interferon alpha 2B in previously untreated patients with hepatocellular carcinoma. Cancer 1990 ; 66: 135–139. MEDLINE
25. 25 Melamed D, Tiefenbrun N, Yarden A, Kimchi A. Interferons and interleukin‐6 suppress the DNA‐binding activity of E2F in growth‐sensitive hematopoietic cells. Mol Cell Biol 1993 ; 13: 5255–5265. MEDLINE
26. 26 Creasey AA, Bartholomew JC, Merigan TC. Role of G 0 ‐G 1 arrest in the inhibition of tumor cell growth by interferon. Proc Natl Acad Sci U S A 1980 ; 77: 1471–1475. MEDLINE
27. 27 Roos G, Leanderson T, Lundgren E. Interferon‐induced cell cycle changes in human hematopoietic cell lines and fresh leukemic cells. Cancer Res 1984 ; 44: 2358–2362. MEDLINE
28. 28 Qin XQ, Runkel L, Deck C, DeDios C, Barsoum J. Interferon‐β induces S phase accumulation selectively in human transformed cells. J Interferon Cytokine Res 1997 ; 17: 355–367. MEDLINE
29. 29 Numa Y, Kawamoto K, Sakai N, Matsumura H. Flow cytometric analysis of antineoplastic effects of interferon‐α, β and γ labelled with fluorescein isothiocyanate on cultured brain tumors. J Neuro‐Oncol 1991 ; 11: 225–234.
30. 30 Schiller JH, Bittner G, Meisner LF, Oberley TD, Norback D, Schwabe M, Faltynek CR, et al. Establishment and characterization of an Epstein‐Barr virus spontaneously transformed lymphocytic cell line derived from a hairy cell leukemia patient. Leukemia 1990 ; 5: 399–407.
31. 31 Nikolaeva TG, Timofeev IV, Dobrynin Ia V. Effect of interferon on cell cycle phases in cultured human tumor cells. Eksp Onkol 1984 ; 6: 52–55. MEDLINE
32. 32 Balkwill F, Taylor‐Papadimitriou J. Interferon affects both G 1 and S+G 2 in cells stimulated from quiescence to growth. Nature 1978 ; 274: 798–800. MEDLINE
33. 33 Sangfelt O, Erickson S, Castro J, Heiden T, Einhorn S, Grandér D. Induction of apoptosis and inhibition of cell growth are independent responses to interferon‐α in hematopoietic cell lines. Cell Growth Differ 1997 ; 8: 343–352. MEDLINE
34. 34 Sokawa Y, Watanabe Y, Watanabe Y, Kawade K. Interferon suppresses the transition of quiescent 3T3 cells to a growing state. Nature 1977 ; 268: 236–238. MEDLINE
35. 35 Buechner SA, Wernli M, Harr T, Hahn S, Itin P, Erb P. Progression of basal cell carcinoma by intralesional interferon‐alpha treatment is mediated by CD95 (Apo‐1/Fas)‐CD95 ligand‐induced suicide. J Clin Invest 1997 ; 100: 2691–2696. MEDLINE
36. 36 Tarumi T, Sawada K, Sato N, Kobayashi S, Takano H, Yasukouchi T, Takahashi T, et al. Interferon‐α–induced apoptosis in human erythroid progenitors. Exp Hematol 1995 ; 23: 1310–1318. MEDLINE
37. 37 Rodríguez‐Villanueva J, MacDonnell TJ. Induction of apoptotic cell death in non‐melanoma skin cancer by interferon‐α. Int J Cancer 1995 ; 61: 110–114. MEDLINE
38. 38 Selleri C, Sato T, Vecchio LD, Luciano L, Barrett AJ, Rotoli B, Young NS, et al. Involvement of Fas‐mediated apoptosis in the inhibitory effects of interferon‐α in chronic myelogenous leukemia. Blood 1997 ; 89: 957–964. MEDLINE
39. 39 Huber BE, Wirth PJ, Newbold JE. Effects of human lymphoblastoid interferon on proliferation, gene expression and tumourigenicity of human hepatoma cell lines. Drugs Exp Clin Res 1991 ; 17: 281–291. MEDLINE
40. 40 Dunk AA, Ikeda T, Pignatelli M, Thomas HC. Human lymphoblastoid interferon: in vitro and in vivo studies in hepatocellular carcinoma. J Hepatol 1986 ; 2: 419–429. MEDLINE
41. 41 Murakami T. Establishment and characterization of human hepatoma cell line (KIM‐1). Acta Hepatol Jpn 1984 ; 25: 532–539.
42. 42 Yano H, Kojiro M, Nakashima T. A new human hepatocellular carcinoma cell line (KYN‐1) with a transformation to adenocarcinoma. In Vitro Cell Dev Biol 1986 ; 22: 637–646. MEDLINE
43. 43 Yano H, Maruiwa M, Murakami T, Fukuda K, Ito Y, Sugihara S, Kojiro M. A new human pleomorphic hepatocellular carcinoma cell line, KYN‐2. Acta Pathol Jpn 1988 ; 38: 953–966. MEDLINE
44. 44 Murakami T, Maruiwa M, Fukuda K, Kojiro M, Tanaka M, Tanikawa K. Characterization of a new human hepatoma cell line (KYN‐3) derived from the ascites of the hepatoma patient [Abstract]. Jpn J Cancer Res 1988 ; Proceedings of the Japanese Cancer Association: 292.
45. 45 Yano H, Iemura A, Fukuda K, Mizoguchi A, Haramaki M, Kojiro M. Establishment of two distinct human hepatocellular carcinoma cell lines from a single nodule showing clonal dedifferentiation of cancer cells. Hepatology 1993 ; 18: 320–327. MEDLINE
46. 46 Haramaki M, Yano H, Iemura A, Momosaki S, Ogasawara S, Inoue M, Yamaguchi R, et al. A new human hepatocellular carcinoma cell line (HAK‐2) forms various structures in collagen gel matrices. Hum Cell 1997 ; 10: 183–192. MEDLINE
47. 47 Murakami T, Yano H, Maruiwa M, Sugihara S, Kojiro M. Establishment and characterization of a human combined hepatocholangiocarcinoma cell line and its heterologous transplantation in nude mice. Hepatology 1987 ; 7: 551–556. MEDLINE
48. 48 Yano H, Iemura A, Haramaki M, Momosaki S, Ogasawara S, Higaki K, Kojiro M. A human combined hepatocellular and cholangiocarcinoma cell line (KMCH‐2) that shows the features of hepatocellular carcinoma or cholangiocarcinoma under different growth conditions. J Hepatol 1996 ; 24: 413–422. MEDLINE
49. 49 Harada H, Kondo T, Ogawa S, Tamura T, Kitagawa M, Tanaka N, Lamphier MS, et al. Accelerated exon skipping of IRF‐1 mRNA in human myelodysplasia/leukemia; a possible mechanism of tumor suppressor inactivation. Oncogene 1994 ; 9: 3313–3320. MEDLINE
50. 50 Yano H, Fukuda K, Haramaki M, Momosaki S, Ogasawara S, Higaki K, Kojiro M. Expression of Fas and anti‐Fas–mediated apoptosis in human hepatocellular carcinoma cell lines. J Hepatol 1996 ; 25: 454–464. MEDLINE
51. 51 Yano H, Mizoguchi A, Fukuda K, Haramaki M, Ogasawara S, Momosaki S, Kojiro M. The herbal medicine Sho‐saiko‐to inhibits proliferation of cancer cell lines by inducing apoptosis and arrest at the G 0 /G 1 phase. Cancer Res 1994 ; 54: 448–454. MEDLINE
52. 52 Novick D, Cohen B, Rubinstein M. Soluble interferon‐α receptor molecules are present in body fluids. FEBS Lett 1992 ; 314: 445–448. MEDLINE
53. 53 Yatsuhashi H, Yano M. Interferon receptor [in Japanese]. KAN•TAN•SUI 1997 ; 35: 457–462.
54. 54 Chaouchi N, Wallon C, Taieb J, Auffredou MT, Tertian G, Lemoine FM, Delfraissy JF, et al. Interferon‐α–mediated prevention of in vitro apoptosis of chronic lymphocytic leukemia B cells: role of bcl‐2 and c‐myc. Clin Immunol Immunopathol 1994 ; 73: 197–204. MEDLINE
55. 55 Jewell AP, Worman CP, Lydyard PM, Yong KL, Giles FJ, Goldstone AH. Interferon‐α up‐regulates bcl‐2 expression and protects B‐CLL cells from apoptosis in vitro and in vivo. Br J Haematol 1994 ; 88: 268–74. MEDLINE
56. 56 Adams JM, Cory S. The Bcl‐2 protein family: arbiters of cell survival. Science 1998 ; 281: 1322–1326. MEDLINE
57. 57 Burke LC, Bybee A, Thomas SB. The retinoblastoma protein is partially phosphorylated during early G 1 in cycling cells but not in G 1 cells arrested with α‐interferon. Oncogene 1992 ; 7: 783–788. MEDLINE
58. 58 Kumar R, Atlas I. Interferon α induces the expression of retinoblastoma gene product in human Burkitt lymphoma Daudi cells: role in growth regulation. Proc Natl Acad Sci U S A 1992 ; 89: 6599–6603. MEDLINE
59. 59 Mandal M, Bandyopadhyay D, Goepfert TM, Kumar R. Interferon‐induces expression of cyclin‐dependent kinase‐inhibitors p21 WAF1 and p27 Kip1 that prevent activation of cyclin‐dependent kinase by CDK‐activating kinase (CAK). Oncogene 1998 ; 16: 217–225. MEDLINE
60. 60 Sangfelt O, Erickson S, Einhorn S, Grandér D. Induction of Cip/Kip and Ink4 cyclin dependent kinase inhibitors by interferon‐α in hematopoietic cell lines. Oncogene 1997 ; 14: 415–423. MEDLINE
61. 61 Subramaniam PS, Johnson HM. A role for the cyclin‐dependent kinase inhibitor p21 in the G 1 cell cycle arrest mediated by the type I interferons. J Interferon Cytokine Res 1997 ; 17: 11–15. MEDLINE
62. 62 Zhang K, Kumar R. Interferon‐α inhibits cyclin‐E and cyclin D1–dependent CDK‐2 kinase activity associated with Rb protein and E2F in Daudi cells. Biochem Biophys Res Commun 1994 ; 200: 522–528. MEDLINE
63. 63 Hobeika AC, Subramaniam PS, Johnson HM. IFNα induces the expression of the cyclin‐dependent kinase inhibitor p21 in human prostate cancer cells. Oncogene 1997 ; 14: 1165–1170. MEDLINE
64. 64 Mazzella G, Accogli E, Sottili S, Festi D, Orsini M, Salzetta A, Novelli V, et al. Alpha interferon treatment may prevent hepatocellular carcinoma in HCV‐related liver cirrhosis. J Hepatol 1996 ; 24: 141–147. MEDLINE
65. 65 Nishiguchi S, Kuroki T, Nakatani S, Morimoto H, Takeda T, Nakajima S, Shiomi S, et al. Randomised trial of effects of interferon‐α on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 1995 ; 346: 1051–1055. MEDLINE
66. 66 Kasahara A, Hayashi N, Mochizuki K, Takayanagi M, Yoshioka K, Kakumu S, Iijima A, et al. Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Hepatology 1998 ; 27: 1394–1402. MEDLINE
67. 67 Tsubura E. The phase I and early phase II studies of human lymphoblast interferon (MOR‐22) in the treatment of malignant tumors. J Jpn Soc Cancer Ther 1986 ; 21: 1049–1058.
68. 68 Kishida T. Phase I study of OPC‐18 (natural IFN‐α). Clinical Report 1994 ; 28: 3539–3545.